Morningstar flags market pessimism on Aussie co Clinuvel's drug rollout

Clinuvel Pharmaceuticals

08/07/2025 06:47

Updates

** Clinuvel Pharmaceuticals CUV.AX rises 4.2% to A$10.51

** Stock down 14.1% since reporting interim results in February, despite no major announcements as of last close

** Morningstar says, "We suspect the market is likely too pessimistic on the speed and extent of CUV's commercial roll-out of Scenesse for its existing indication, which contributes 80% to our fair value estimate"

** Scenesse is used to treat a rare condition that causes severe pain after exposure to the sun

** Brokerage says, "Stock materially undervalued as we remain optimistic about demand for Scenesse and margin expansion"

** CUV rated "buy" on avg; median PT is A$23.08, per LSEG-compiled data

** YTD, stock down ~13%

 (Reporting by Sherin Sunny & Shruti Agarwal in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com;))